Cargando…

Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking

To explore the potential active compounds and molecular mechanism of Xuefu Zhuyu decoction (XFZYD) in the treatment of atherosclerosis (AS) based on network pharmacology and molecular docking. The effective components and action targets of XFZYD were screened by using TCMSP database. And then, the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yingyun, Liu, Boyu, Liu, Lin, Xu, Qing, Shen, Quan, Li, Weikang, Zhao, Jingshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371493/
https://www.ncbi.nlm.nih.gov/pubmed/35960089
http://dx.doi.org/10.1097/MD.0000000000029654
_version_ 1784767156022411264
author Li, Yingyun
Liu, Boyu
Liu, Lin
Xu, Qing
Shen, Quan
Li, Weikang
Zhao, Jingshan
author_facet Li, Yingyun
Liu, Boyu
Liu, Lin
Xu, Qing
Shen, Quan
Li, Weikang
Zhao, Jingshan
author_sort Li, Yingyun
collection PubMed
description To explore the potential active compounds and molecular mechanism of Xuefu Zhuyu decoction (XFZYD) in the treatment of atherosclerosis (AS) based on network pharmacology and molecular docking. The effective components and action targets of XFZYD were screened by using TCMSP database. And then, the action targets of AS were collected by GeneCards database. The intersection targets between the effective components’ targets of XFZYD and AS-related action targets were used to construct PPI networks. GO and Kyoto Encyclopedia of Genes and Genomes enrichment analysis were performed on these intersection targets. Finally, molecular docking software was used to excavate the active compounds of the core targets VEGFA and AKT1. We detected 225 active components of XFZYD, and found that quercetin, kaempferol, luteolin, naringenin, β-sitosterol, isorhamnetin, stigmasterol, baicalein, nobiletin, and β-carotene are the potential active compounds of XFZYD; STAT3, IL6, JUN, VEGFA, MAPK14, and AKT1 are the core target proteins of the active compounds, among which VEGFA and AKT1 are the key target proteins. PPI network results showed that β-carotene, quercetin, kaempferol, luteolin, and naringenin had higher degree values and more corresponding targets than other 5 active compounds and had the stable binding ability to regulatory proteins VEGFA and AKT1. The core components β-carotene, quercetin, kaempferol, and luteolin exerted their therapeutic effects on AS by acting on the key target proteins VEGFA and AKT1 to regulate fluid shear stress and the AGE-RAGE signaling pathway and IL-17 signaling pathway of diabetic complications of AS. The molecular docking results showed that VEGFA and AKT1 had great docking ability with the targeted active compounds, and β-carotene is the best. The active components of XFZYD, including β -carotene, quercetin, kamanol, and luteolin, can act on VEGFA and AKT1. These active ingredients play a role in alleviating and treating AS by regulating fluid shear stress and participating in signaling pathways such AS AGE-RAGE of atherosclerosis and diabetes mellitus complicated with AS. β-carotene is a potential inhibitor of VEGFA and AKT1 and treats AS through antioxidant action.
format Online
Article
Text
id pubmed-9371493
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93714932022-08-16 Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking Li, Yingyun Liu, Boyu Liu, Lin Xu, Qing Shen, Quan Li, Weikang Zhao, Jingshan Medicine (Baltimore) Research Article To explore the potential active compounds and molecular mechanism of Xuefu Zhuyu decoction (XFZYD) in the treatment of atherosclerosis (AS) based on network pharmacology and molecular docking. The effective components and action targets of XFZYD were screened by using TCMSP database. And then, the action targets of AS were collected by GeneCards database. The intersection targets between the effective components’ targets of XFZYD and AS-related action targets were used to construct PPI networks. GO and Kyoto Encyclopedia of Genes and Genomes enrichment analysis were performed on these intersection targets. Finally, molecular docking software was used to excavate the active compounds of the core targets VEGFA and AKT1. We detected 225 active components of XFZYD, and found that quercetin, kaempferol, luteolin, naringenin, β-sitosterol, isorhamnetin, stigmasterol, baicalein, nobiletin, and β-carotene are the potential active compounds of XFZYD; STAT3, IL6, JUN, VEGFA, MAPK14, and AKT1 are the core target proteins of the active compounds, among which VEGFA and AKT1 are the key target proteins. PPI network results showed that β-carotene, quercetin, kaempferol, luteolin, and naringenin had higher degree values and more corresponding targets than other 5 active compounds and had the stable binding ability to regulatory proteins VEGFA and AKT1. The core components β-carotene, quercetin, kaempferol, and luteolin exerted their therapeutic effects on AS by acting on the key target proteins VEGFA and AKT1 to regulate fluid shear stress and the AGE-RAGE signaling pathway and IL-17 signaling pathway of diabetic complications of AS. The molecular docking results showed that VEGFA and AKT1 had great docking ability with the targeted active compounds, and β-carotene is the best. The active components of XFZYD, including β -carotene, quercetin, kamanol, and luteolin, can act on VEGFA and AKT1. These active ingredients play a role in alleviating and treating AS by regulating fluid shear stress and participating in signaling pathways such AS AGE-RAGE of atherosclerosis and diabetes mellitus complicated with AS. β-carotene is a potential inhibitor of VEGFA and AKT1 and treats AS through antioxidant action. Lippincott Williams & Wilkins 2022-08-12 /pmc/articles/PMC9371493/ /pubmed/35960089 http://dx.doi.org/10.1097/MD.0000000000029654 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Yingyun
Liu, Boyu
Liu, Lin
Xu, Qing
Shen, Quan
Li, Weikang
Zhao, Jingshan
Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking
title Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking
title_full Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking
title_fullStr Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking
title_full_unstemmed Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking
title_short Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking
title_sort potential active compounds and molecular mechanism of xuefu zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371493/
https://www.ncbi.nlm.nih.gov/pubmed/35960089
http://dx.doi.org/10.1097/MD.0000000000029654
work_keys_str_mv AT liyingyun potentialactivecompoundsandmolecularmechanismofxuefuzhuyudecoctionforatherosclerosisbasedonnetworkpharmacologyandmoleculardocking
AT liuboyu potentialactivecompoundsandmolecularmechanismofxuefuzhuyudecoctionforatherosclerosisbasedonnetworkpharmacologyandmoleculardocking
AT liulin potentialactivecompoundsandmolecularmechanismofxuefuzhuyudecoctionforatherosclerosisbasedonnetworkpharmacologyandmoleculardocking
AT xuqing potentialactivecompoundsandmolecularmechanismofxuefuzhuyudecoctionforatherosclerosisbasedonnetworkpharmacologyandmoleculardocking
AT shenquan potentialactivecompoundsandmolecularmechanismofxuefuzhuyudecoctionforatherosclerosisbasedonnetworkpharmacologyandmoleculardocking
AT liweikang potentialactivecompoundsandmolecularmechanismofxuefuzhuyudecoctionforatherosclerosisbasedonnetworkpharmacologyandmoleculardocking
AT zhaojingshan potentialactivecompoundsandmolecularmechanismofxuefuzhuyudecoctionforatherosclerosisbasedonnetworkpharmacologyandmoleculardocking